GBLX - GB Sciences, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0335
0.0000 (0.00%)
At close: 3:55PM EDT
Stock chart is not supported by your current browser
Previous Close0.0335
Open0.0265
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0265 - 0.0348
52 Week Range0.0200 - 0.1900
Volume441,293
Avg. Volume458,166
Market Cap9.138M
Beta (5Y Monthly)-0.02
PE Ratio (TTM)N/A
EPS (TTM)-0.0500
Earnings DateAug 14, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GB Sciences Announces Outstanding Results from Preclinical Study of Its Parkinson's Disease Formulations
    PR Newswire

    GB Sciences Announces Outstanding Results from Preclinical Study of Its Parkinson's Disease Formulations

    GB Sciences, Inc. (OTCQB: GBLX) announced significant preclinical results for their Parkinson's disease ("PD") formulations from the midterm report for their preclinical study being performed by Dr. Lee Ellis of the National Research Council (NRC) in Halifax, Nova Scotia, CANADA. GB Sciences' PD formulations were able to reduce behavioral changes associated with the loss of dopamine-producing neurons, which underlies the pathology of Parkinson's disease in the animal model. Our final phase of testing will study the mechanism of action for these promising formulations, which could potentially help patients with this debilitating disease. The combined direct and indirect costs associated with Parkinson's disease are estimated at $52 billion in the U.S. alone.

  • GB Sciences Announces the Sale of The Majority Interest in Nevada Cultivation Operations to Focus on Its First Two Cannabinoid-Based Medical Compounds for Parkinson's Disease and Neuropathic Pain
    CNW Group

    GB Sciences Announces the Sale of The Majority Interest in Nevada Cultivation Operations to Focus on Its First Two Cannabinoid-Based Medical Compounds for Parkinson's Disease and Neuropathic Pain

    LAS VEGAS , Dec. 5, 2019 /CNW/ -- GB Sciences, Inc. (GBLX) announced the execution of a Binding Letter of Intent for the Sale of 75% of its membership interests in the Company's Las Vegas, Nevada cultivation and production operation. This transaction will significantly reduce the Company's operating expenses, generate near-term working capital, and provide ongoing cashflow to enable the Company to focus solely on its biopharmaceutical and wellness assets. The transaction is the next step in the Company's exit from cannabis cultivation and production.

  • GB Sciences Closes the Sale of GB Sciences Louisiana Cannabis Business to Wellcana Plus and Retains the Benefit of IP Developed Under GB Sciences Louisiana's Master Research and Development Agreement
    CNW Group

    GB Sciences Closes the Sale of GB Sciences Louisiana Cannabis Business to Wellcana Plus and Retains the Benefit of IP Developed Under GB Sciences Louisiana's Master Research and Development Agreement

    The Sale, Which Immediately Eliminates Substantial Cash Obligations and Operating Expenses, Is Collateralized by Wellcana Plus's Interest in GB Sciences Louisiana. LAS VEGAS , Nov. 18, 2019 /CNW/ -- GB Sciences, Inc. (GBLX) completed the sale on November 15, 2019 of its 50% membership interest in GB Sciences Louisiana, LLC to Wellcana Plus, LLC, an affiliate of Wellcana Group, LLC who owns the other 50% interest. The sale immediately eliminates current cash obligations due from GB Sciences as well as the Company's share of operating expenses going forward.

  • The Closing Date of GB Sciences' Sale of GB Sciences Louisiana LLC Is Delayed
    PR Newswire

    The Closing Date of GB Sciences' Sale of GB Sciences Louisiana LLC Is Delayed

    LAS VEGAS, Nov. 6, 2019 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announces a delay in the sale of GB Sciences Louisiana LLC. On September 16, 2019, GB Sciences, Inc. (the "Company"), filed a Current Report on Form 8-K disclosing that the Company had signed a term sheet with K2 Logic, LLC ("K2") pursuant to which K2 will pursue the purchase of the Company's 50% ownership interest in GB Science Louisiana, LLC for $8,000,000 in cash and earn out provisions for up to an additional $8,000,000. GB Sciences, Inc. (GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development.

  • GB Sciences Welcomes Esteemed Patent and Intellectual Property Attorney, Mr. Edmond DeFrank, to Its Board of Directors
    PR Newswire

    GB Sciences Welcomes Esteemed Patent and Intellectual Property Attorney, Mr. Edmond DeFrank, to Its Board of Directors

    LAS VEGAS, Oct. 31, 2019 /PRNewswire/ -- GB Sciences, Inc. (GBLX) is pleased to announce that on October 23rd Mr. Edmond DeFrank joined its Board of Directors, filling a vacant seat. Mr. DeFrank is an attorney in the cannabis sector with deep expertise in patents and intellectual property. Mr. DeFrank brings a host of skills and experience beneficial to the Company.

  • GB Sciences' Chief Science Officer Featured on the Cover of the Marijuana Business Magazine
    PR Newswire

    GB Sciences' Chief Science Officer Featured on the Cover of the Marijuana Business Magazine

    LAS VEGAS, Oct. 9, 2019 /PRNewswire/ -- GB Sciences, Inc. (GBLX) is featured in the October 2019 edition of the Marijuana Business Magazine. Dr. Andrea Small-Howard, GB Sciences' Chief Science Officer and Director, explains why GB Sciences is well-positioned to provide research-supported product formulations for both market segments.

  • GB Sciences Sells Its Louisiana Medical Marijuana Business At A $32 Million Total Valuation
    PR Newswire

    GB Sciences Sells Its Louisiana Medical Marijuana Business At A $32 Million Total Valuation

    LAS VEGAS, Sept. 17, 2019 /PRNewswire/ -- GB Sciences, Inc. (GBLX), on Friday, September 13, 2019, filed an 8k announcing the sale of its 50% ownership stake in GB Sciences Louisiana, LLC.  The stake will be purchased by Wellcana Plus LLC, affiliated through its managers with the group which holds the other 50% of the Louisiana operations.  Expected to close by the end of October 2019, the sale is for $16 million to GB Sciences, $7 million in cash at closing, $1 million in cash within 60 days of closing, and the remaining $8 million as an earn out.  The actual proceeds realized through the earn out and the timing of those proceeds will depend upon the profitability of the Louisiana operations. The sale will greatly reduce the current and future burn rate of the Company and allow it to focus on achieving profitability, seeking a DEA license, and implementing GMP, a set of regulations promulgated by the US Food and Drug Administration to ensure quality control in the manufacture of pharmaceuticals, dietary supplements and natural health products among other substances, at its Las Vegas, Nevada location.

  • U.S. Drug Enforcement Agency to Expand Cannabis Research: GB Sciences Submitted One of Thirty-Three Applications to Become a DEA-Registered Cannabis Supplier to U.S. Marijuana Researchers
    CNW Group

    U.S. Drug Enforcement Agency to Expand Cannabis Research: GB Sciences Submitted One of Thirty-Three Applications to Become a DEA-Registered Cannabis Supplier to U.S. Marijuana Researchers

    U.S. Drug Enforcement Agency to Expand Cannabis Research: GB Sciences Submitted One of Thirty-Three Applications to Become a DEA-Registered Cannabis Supplier to U.S. Marijuana Researchers

  • GB Sciences Names Darin Carpenter as Executive Vice President of Cannabis Operations
    PR Newswire

    GB Sciences Names Darin Carpenter as Executive Vice President of Cannabis Operations

    LAS VEGAS, Aug. 28, 2019 /PRNewswire/ -- GB Sciences, Inc. (GBLX) today announced the appointment to GB Sciences' executive team of Darin Carpenter as the company's new Executive Vice President for Operations and General Manager, bringing his extensive and nationally-recognized experience streamlining production, improving product quality, and increasing profitability to GBS.

  • GB Sciences Prepares To Launch New Products In Louisiana With Educational Seminars For Doctors And Pharmacists
    PR Newswire

    GB Sciences Prepares To Launch New Products In Louisiana With Educational Seminars For Doctors And Pharmacists

    Education program includes evidence-based review of FDA-registered human clinical trial data supporting the use of cannabis to treat approved medical conditions. LAS VEGAS, Aug. 7, 2019 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announced that its subsidiary GB Sciences Louisiana will hold a series of seminars in August, in partnership with state-approved medical cannabis pharmacies and the LSU AgCenter, to further educate Louisiana physicians and pharmacists about the new medical cannabis products that the company will launch in coming months.

  • History Made! GB Sciences Louisiana Announces Medical Cannabis Products Now for Sale for First Time in State History
    PR Newswire

    History Made! GB Sciences Louisiana Announces Medical Cannabis Products Now for Sale for First Time in State History

    BATON ROUGE, La., Aug. 6, 2019 /PRNewswire/ -- GB Sciences Louisiana (GBLX) today announced that its medical cannabis products, developed in partnership with LSU AgCenter's Therapeutic Cannabis Program, are available for sale to qualified patients in the state's nine licensed pharmacies. This is the first time that qualified patients have legal cannabis medicine available under Louisiana law, marking a historic turning point for patients, advocates, and regulators. "This is a watershed moment for our company and the State of Louisiana, reflecting many years of research and development by GB Sciences into the cannabis plant's biopharmaceutical applications," said John Davis, President of GB Sciences Louisiana.

  • GB Sciences Files Novel Patent Application For Chronic Pain Treatments Based On Proprietary Cannabis-Derived Formulations
    CNW Group

    GB Sciences Files Novel Patent Application For Chronic Pain Treatments Based On Proprietary Cannabis-Derived Formulations

    GB Sciences Files Novel Patent Application For Chronic Pain Treatments Based On Proprietary Cannabis-Derived Formulations

  • GB Sciences Obtains Exclusive License for Patented Oral Thin Film Technology Containing Cannabis and Hemp-Derived Ingredients
    PR Newswire

    GB Sciences Obtains Exclusive License for Patented Oral Thin Film Technology Containing Cannabis and Hemp-Derived Ingredients

    GB Sciences' new oral thin films will be sold in Louisiana and Nevada, reflecting the company's commitment to providing advanced medical cannabis products. Oral thin films are rapidly gaining popularity due to their efficacy, convenience, and discreteness, and sales are increasing rapidly in major cannabis markets including California and Colorado.

  • GBS Global Biopharma and National Research Council of Canada Begin Preclinical Studies on Chronic-Neuropathic Pain Therapies
    CNW Group

    GBS Global Biopharma and National Research Council of Canada Begin Preclinical Studies on Chronic-Neuropathic Pain Therapies

    OTTAWA, Ontario , May 28, 2019 /CNW/ -- GBS Global Biopharma, Inc. ("GBS Global"), a Canadian-based subsidiary of GB Sciences, Inc. (GBLX), announced preclinical studies on their proprietary chronic-neuropathic pain formulations in collaboration with the National Research Council ("NRC") Canada under the direction of Dr. Lee Ellis at NRC laboratories in Halifax, Nova Scotia . Growing public and government concerns regarding opioid abuse make novel pain treatments a promising field of research and development.

  • GB Sciences Prepares to Triple Production Capabilities in Its Las Vegas Facility
    PR Newswire

    GB Sciences Prepares to Triple Production Capabilities in Its Las Vegas Facility

    Positioned to Increase Revenue by Approximately $5.6 Million LAS VEGAS , May 14, 2019 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) today announced it is nearing completion of $700,000 in power and water ...

  • GB Sciences Louisiana Receives All Approvals and Announces the Opening of the Full Tissue Propagation Cannabis Cultivation at LSU Agricultural Center
    PR Newswire

    GB Sciences Louisiana Receives All Approvals and Announces the Opening of the Full Tissue Propagation Cannabis Cultivation at LSU Agricultural Center

    Increases production and ensures a continuous supply of therapeutic cannabis for Louisiana patients. LAS VEGAS, April 16, 2019 /PRNewswire/ -- GB Sciences, Inc. (GBLX), a partner in GB Sciences Louisiana, LLC, is announcing that all cultivation operations at LSU Agricultural Center are now open. This will allow a continuous harvest for patients by increasing GB Sciences Louisiana's production capacity 500%.

  • Today: GB Sciences' Use of Controlled Cultivation, Product Formulations and Research Will Be Presented by Dr. Dominick Monaco at Cannabis Conference 2019, As Featured on Cover of Cannabis Business Times
    PR Newswire

    Today: GB Sciences' Use of Controlled Cultivation, Product Formulations and Research Will Be Presented by Dr. Dominick Monaco at Cannabis Conference 2019, As Featured on Cover of Cannabis Business Times

    LAS VEGAS, April 2, 2019 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announced that Dr. Dominick Monaco, GB Sciences' Director of Medical Formulations, will be a featured speaker at the Las Vegas Cannabis Conference TODAY, April 2, at 4:40pm. Learn more here.

  • GB Sciences Study Shows Nevada's Cannabis Strain Names Have No Correlation to Active Ingredients
    PR Newswire

    GB Sciences Study Shows Nevada's Cannabis Strain Names Have No Correlation to Active Ingredients

    LAS VEGAS, March 28, 2019 /PRNewswire/ -- GB Sciences, Inc. (GBLX) today announced results from a new study that shows only three chemical varieties of cannabis were sold in the Nevada dispensaries between January 2016 and June 2017-- despite nearly 400 different "strain names" appearing on product packaging. Co-authored by GB Sciences, Chaminade University, Makai Biotechnology and Digipath Labs, and published in the journal Cannabis and Cannabinoid Research, the study reveals extremely low chemical diversity within the cannabis varieties sold in the Nevada market during its medical-only phase.

  • In Case You Missed It: GB Sciences Approved For Full Operations In Main LSU AgCenter Production Facility
    PR Newswire

    In Case You Missed It: GB Sciences Approved For Full Operations In Main LSU AgCenter Production Facility

    With over five times the production capacity, main facility will allow for a perpetual harvest cycle, ensuring a continuous supply of therapeutic cannabis for patients throughout Louisiana. LAS VEGAS, March 26, 2019 /PRNewswire/ -- GB Sciences, Inc. (GBLX) today announced that The LSU Agricultural Center (AgCenter) received confirmation from the Louisiana Department of Agriculture and Forestry (LDAF) that GB Sciences Louisiana is deemed suitable for full-scale operations.

  • Market Exclusive

    GB Sciences Hits Milestone After Teaming With LSU Agricultural Research Center

    In November last year, GB Sciences Inc. (OTCMKTS:GBLX) agreed to work together with Louisiana State University Agricultural Center focusing on cannabis. Notably, the two institutions would cooperate in research and development on cannabis with a keen eye on its therapeutic properties. The partnership has hit the first milestone with the maiden harvesting of cannabis. Leveraging […] The post GB Sciences Hits Milestone After Teaming With LSU Agricultural Research Center appeared first on Market Exclusive.

  • ACCESSWIRE

    Marijuana Stocks for Investors in the Free Cannabis Investor Magazine

    MIAMI, FL / ACCESSWIRE / May 7, 2018 / Cannabis Investor Magazine , the leading industry investment magazine for cannabis investors, analysts, executives, entrepreneurs, and financial media, announced ...

  • ACCESSWIRE

    GB Sciences is Exploring a Cannabis Therapy for Parkinson's, Analysts Review

    The company recently announced that it is planning to file an Exploratory IND and perform a Phase 0 Clinical Trial to gather valuable First-In-Human data on its proprietary cannabis-based therapies for the treatment of early to moderate Parkinson's disease. The GB Sciences' Exploratory IND program is designed to allow the company to make informed, data-driven choices in selecting and prioritizing the development of multiple, related drug compositions and formulations. Furthermore, the transaction also enables GB Sciences with access to three licenses from the state of Nevada for cultivation and production of marijuana along with the one for running a dispensary.

  • ACCESSWIRE

    GVC Capital and Trickle Research Announce Presenter Schedule for Rocky Mountain MicroCap Conference II in Denver on April 24, 2018

    DENVER, CO / ACCESSWIRE / April 20, 2018 / GVC Capital LLC ("GVC") and Dave Lavigne at Trickle Research LLC ("Trickle Research") will host the Rocky Mountain MicroCap Conference II ...